ALPHAMAB ONCOLO.DL-000002 (3NK) — Net Asset Quality Index
ALPHAMAB ONCOLO.DL-000002 (3NK) has a Net Asset Quality Index of 81.6% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €2.10 Billion minus total liabilities of €386.17 Million yields net assets of €1.71 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read total liabilities of ALPHAMAB ONCOLO.DL-000002 for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
ALPHAMAB ONCOLO.DL-000002 Net Asset Quality Index Over Time (2021–2025)
This chart shows how ALPHAMAB ONCOLO.DL-000002's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at 81.6%, representing net assets of €1.71 Billion against total assets of €2.10 Billion EUR. For live market cap and overall valuation, see ALPHAMAB ONCOLO.DL-000002 market capitalisation.
Annual Net Asset Quality Index for ALPHAMAB ONCOLO.DL-000002 (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for ALPHAMAB ONCOLO.DL-000002 from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. See ALPHAMAB ONCOLO.DL-000002 net assets for net asset value and shareholders' equity analysis.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 81.6% | €1.71 Billion | €2.10 Billion | €386.17 Million | ▼ -0.1 pp |
| 2024 | 81.7% | €1.83 Billion | €2.24 Billion | €409.87 Million | ▲ +3.5 pp |
| 2023 | 78.2% | €1.67 Billion | €2.14 Billion | €465.00 Million | ▲ +4.7 pp |
| 2022 | 73.6% | €1.56 Billion | €2.12 Billion | €559.86 Million | ▲ +4.4 pp |
| 2021 | 69.1% | €1.87 Billion | €2.71 Billion | €834.80 Million | — |